Reports Q2 revenue $1.42B, consensus $1.4B. “Our second quarter results demonstrate the strength and resilience of our global business as we continue advancing our mission to help people sleep better, breathe better, and live longer and healthier lives in the comfort of their own home,” said Resmed’s (RMD) chairman and CEO, Mick Farrell.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Is RMD a Buy, Before Earnings?
- ResMed price target lowered to $260 from $270 at Stifel
- ResMed downgraded to Neutral from Outperform at Baird
- ResMed receives FDA clearance for PTCS to be marketed as Smart Comfort
- Resmed’s Strategic Positioning and Market Valuation Suggest 19% Upside Despite Future CMS Challenges